Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

(2019) Emanuel Raschi et al.   Targeted Oncology

Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series

(2019) Jenna May Kim et al.   OPHTHALMOLOGY

Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS

(2019) Huan-huan Ji et al.   CLINICAL DRUG INVESTIGATION

Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy

(2019) Karen Bitton et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies

(2019) Carl W. Noble et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System

(2019) Emanuel Raschi et al.   ONCOLOGIST

Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

(2019) David Bomze et al.   JAMA Oncology

Cardiovascular Toxicities Associated With Ibrutinib

(2019) Joe-Elie Salem et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

(2019) Jianchun Duan et al.   JAMA Oncology

CHECKPOINT INHIBITOR IMMUNE THERAPY

(2018) Lauren A. Dalvin et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

(2018) Alexander N. Shoushtari et al.   JAMA Oncology

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

(2017) Omar Abdel-Rahman et al.   Expert Review of Anticancer Therapy

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocular and orbital side-effects of checkpoint inhibitors

(2016) Joëlle Antoun et al.   CURRENT OPINION IN ONCOLOGY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature

(2015) Evangelia Papavasileiou et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Choosing Thresholds for Statistical Signal Detection with the Proportional Reporting Ratio

(2013) Jim Slattery et al.   DRUG SAFETY

Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma

(2009) Steven Yeh et al.   OPHTHALMOLOGY

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY